Evidence map›Paper›PMID 42509348›Full record

ArticleNature biomedical engineering2026

A PET reporter ligand for quantitative imaging of gene expression in the brain.

Sophie Stotz, Gina Dunkel, Sabrina Haas, Philipp Seyfried, Johannes Kinzler, Jacqueline Berner, Martin Schaller, Michael Lämmerhofer, Seth G N Grant, Bernd J Pichler and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sophie StotzWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Tuebingen, Germany. sophie.stotz@sund.ku.dk.ORCID http://orcid.org/0000-0003-4020-1088
Gina DunkelWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Tuebingen, Germany.ORCID http://orcid.org/0009-0003-9543-3959
Sabrina HaasWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Tuebingen, Germany.
Philipp SeyfriedPharmaceutical (Bio-)Analysis, Institute of Pharmaceutical Sciences, Eberhard Karls University Tuebingen, Tuebingen, Germany.
Johannes KinzlerWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Tuebingen, Germany.
Jacqueline BernerWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Tuebingen, Germany.
Martin SchallerDepartment of Dermatology, Eberhard Karls University Tuebingen, Tuebingen, Germany.ORCID http://orcid.org/0000-0002-7930-1919
Michael LämmerhoferPharmaceutical (Bio-)Analysis, Institute of Pharmaceutical Sciences, Eberhard Karls University Tuebingen, Tuebingen, Germany.ORCID http://orcid.org/0000-0002-1318-0974
Seth G N GrantInstitute for Neuroscience and Cardiovascular Research, University of Edinburgh, Edinburgh, UK.
Bernd J PichlerWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Tuebingen, Germany.ORCID http://orcid.org/0000-0001-6784-5524
Bettina WeigelinWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Tuebingen, Germany.ORCID http://orcid.org/0000-0003-4460-3113
Kristina Herfert *Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Tuebingen, Germany.ORCID http://orcid.org/0000-0003-0231-7717
Andreas Maurer *Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Tuebingen, Germany. a.maurer@hzdr.de.ORCID http://orcid.org/0000-0003-2412-5361

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) EXC 2180 - 390900677Novo Nordisk Fonden (Novo Nordisk Foundation) NNF23SA0087869
6 · The paper itself

Abstract

The lack of brain penetrant and biologically stable positron emission tomography reporter systems hampers the development of neurological disease models and the monitoring of gene delivery because existing approaches depend on endogenous receptors that vary unpredictably in pathology. HaloTag, a fully exogenous protein label that forms rapid and irreversible bonds with synthetic ligands, provides a modular platform for engineering reporter probes with defined chemical properties. Here we developed a fluorine-18-labelled small-molecule HaloTag ligand optimized for brain entry and covalent retention at the reporter. The tracer showed specific binding in human cells expressing HaloTag and enabled non-invasive imaging of viral gene transfer to striatal neurons in mice, with clear detection of reporter expressing tissue and rapid clearance from surrounding regions. Optical imaging confirmed viral distribution and reporter expression, and a transgenic model expressing HaloTag fused to a postsynaptic protein demonstrated detection of physiologically expressed intraneuronal targets. This system establishes a modular platform for validating preclinical models and quantifying gene expression in the living brain.

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.